370 related articles for article (PubMed ID: 30967867)
1. Mycobacterial Evolution Intersects With Host Tolerance.
Saelens JW; Viswanathan G; Tobin DM
Front Immunol; 2019; 10():528. PubMed ID: 30967867
[TBL] [Abstract][Full Text] [Related]
2. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis?
Park HE; Lee W; Shin MK; Shin SJ
Front Immunol; 2021; 12():703060. PubMed ID: 34262571
[TBL] [Abstract][Full Text] [Related]
3. The arms race between man and Mycobacterium tuberculosis: Time to regroup.
Hoal EG; Dippenaar A; Kinnear C; van Helden PD; Möller M
Infect Genet Evol; 2018 Dec; 66():361-375. PubMed ID: 28843547
[TBL] [Abstract][Full Text] [Related]
4. Natural and trained innate immunity against Mycobacterium tuberculosis.
Ferluga J; Yasmin H; Al-Ahdal MN; Bhakta S; Kishore U
Immunobiology; 2020 May; 225(3):151951. PubMed ID: 32423788
[TBL] [Abstract][Full Text] [Related]
5. Targeting immunometabolism in host defence against Mycobacterium tuberculosis.
Sheedy FJ; Divangahi M
Immunology; 2021 Feb; 162(2):145-159. PubMed ID: 33020911
[TBL] [Abstract][Full Text] [Related]
6. Evidence for Highly Variable, Region-Specific Patterns of T-Cell Epitope Mutations Accumulating in
Ramaiah A; Nayak S; Rakshit S; Manson AL; Abeel T; Shanmugam S; Sahoo PN; John AJUK; Sundaramurthi JC; Narayanan S; D'Souza G; von Hoegen P; Ottenhoff THM; Swaminathan S; Earl AM; Vyakarnam A
Front Immunol; 2019; 10():195. PubMed ID: 30814998
[TBL] [Abstract][Full Text] [Related]
7. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.
Abreu R; Giri P; Quinn F
Front Immunol; 2020; 11():1553. PubMed ID: 32849525
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Co-evolution of Mycobacterium tuberculosis and Homo sapiens.
Brites D; Gagneux S
Immunol Rev; 2015 Mar; 264(1):6-24. PubMed ID: 25703549
[TBL] [Abstract][Full Text] [Related]
10. Tolerating the Unwelcome Guest; How the Host Withstands Persistent
Olive AJ; Sassetti CM
Front Immunol; 2018; 9():2094. PubMed ID: 30258448
[TBL] [Abstract][Full Text] [Related]
11. Mycobacterial Genetic Technologies for Probing the Host-Pathogen Microenvironment.
Adefisayo OO; Curtis ER; Smith CM
Infect Immun; 2023 Jun; 91(6):e0043022. PubMed ID: 37249448
[TBL] [Abstract][Full Text] [Related]
12. Sensing of Mycobacterium tuberculosis and consequences to both host and bacillus.
Stamm CE; Collins AC; Shiloh MU
Immunol Rev; 2015 Mar; 264(1):204-19. PubMed ID: 25703561
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicles in the context of Mycobacterium tuberculosis infection.
Palacios A; Gupta S; Rodriguez GM; Prados-Rosales R
Mol Immunol; 2021 May; 133():175-181. PubMed ID: 33743266
[TBL] [Abstract][Full Text] [Related]
14. Evolution of virulence in the Mycobacterium tuberculosis complex.
Orgeur M; Brosch R
Curr Opin Microbiol; 2018 Feb; 41():68-75. PubMed ID: 29216510
[TBL] [Abstract][Full Text] [Related]
15. New insights into the evasion of host innate immunity by Mycobacterium tuberculosis.
Chai Q; Wang L; Liu CH; Ge B
Cell Mol Immunol; 2020 Sep; 17(9):901-913. PubMed ID: 32728204
[TBL] [Abstract][Full Text] [Related]
16. Dissecting Host-Pathogen Interactions in TB Using Systems-Based Omic Approaches.
Borah K; Xu Y; McFadden J
Front Immunol; 2021; 12():762315. PubMed ID: 34795672
[TBL] [Abstract][Full Text] [Related]
17. Modeling the potential impact of host population survival on the evolution of M. tuberculosis latency.
Zheng N; Whalen CC; Handel A
PLoS One; 2014; 9(8):e105721. PubMed ID: 25157958
[TBL] [Abstract][Full Text] [Related]
18. Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.
Kiran D; Podell BK; Chambers M; Basaraba RJ
Semin Immunopathol; 2016 Mar; 38(2):167-83. PubMed ID: 26510950
[TBL] [Abstract][Full Text] [Related]
19. Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis.
Guler R; Ozturk M; Sabeel S; Motaung B; Parihar SP; Thienemann F; Brombacher F
Front Immunol; 2021; 12():733853. PubMed ID: 34745105
[TBL] [Abstract][Full Text] [Related]
20. Beyond Killing
Divangahi M; Khan N; Kaufmann E
Front Immunol; 2018; 9():2976. PubMed ID: 30619333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]